EXHIBIT 10.6
STRATEGIC INVESTMENT AGREEMENT
BETWEEN
DIGIMARC CORPORATION
AND
MACROVISION CORPORATION
DATED AS OF SEPTEMBER 17, 2000
TABLE OF CONTENTS
|
|
|
|
PAGE
|
|
|
|
|
|
|
ARTICLE I. PURCHASE AND SALE OF ADDITIONAL
SHARES
|
|
2
|
|
1.1
|
PURCHASE AND SALE OF THE ADDITIONAL
SHARES
|
|
2
|
|
1.2
|
THE CLOSING
|
|
2
|
|
1.3
|
JDA AMENDMENT
|
|
2
|
|
|
|
|
|
|
ARTICLE II. REPRESENTATIONS AND
WARRANTIES
|
|
2
|
|
2.1
|
REPRESENTATIONS AND WARRANTIES OF THE
COMPANY
|
|
2
|
|
2.2
|
REPRESENTATIONS AND WARRANTIES OF THE
INVESTOR
|
|
9
|
|
|
|
|
|
|
ARTICLE III. COVENANTS
|
|
12
|
|
3.1
|
[RESERVED]
|
|
12
|
|
3.2
|
INVESTOR’S STANDSTILL AGREEMENT
|
|
12
|
|
3.3
|
TRANSFER
|
|
13
|
|
3.4
|
COMPLIANCE WITH SECTION 13
|
|
14
|
|
3.5
|
DIRECTOR APPOINTMENTS AND ELECTION
|
|
14
|
|
|
|
|
|
|
ARTICLE IV. REGISTRATION RIGHTS
|
|
12
|
|
4.1
|
LEGEND
|
|
14
|
|
4.2
|
REGISTRATION ON FORM S-3
|
|
15
|
|
4.3
|
PIGGYBACK REGISTRATION
|
|
16
|
|
4.4
|
REGISTRATION PROCEDURES
|
|
17
|
|
4.5
|
DELAY OF REGISTRATION; FURNISHING
INFORMATION
|
|
20
|
|
4.6
|
TERMINATION OF REGISTRATION RIGHTS
|
|
20
|
|
4.7
|
INDEMNIFICATION
|
|
20
|
|
4.8
|
ASSIGNMENT OF REGISTRATION RIGHTS
|
|
23
|
|
4.9
|
LIMITATION ON SUBSEQUENT REGISTRATION
RIGHTS
|
|
23
|
|
4.10
|
MARKET STAND-OFF AGREEMENT
|
|
23
|
|
4.11
|
RULE 144 REPORTING
|
|
24
|
|
|
|
|
|
|
ARTICLE V. ADDITIONAL AGREEMENTS
|
24
|
|
5.1
|
CONSENTS; APPROVALS
|
|
24
|
|
5.2
|
PROCEDURAL SAFEGUARDS
|
|
25
|
|
|
|
|
|
|
ARTICLE VI. CONDITIONS PRECEDENT
|
|
25
|
|
6.1
|
INVESTOR CONDITIONS TO CLOSING
|
|
25
|
|
6.2
|
COMPANY CONDITIONS TO CLOSING
|
|
27
|
|
|
|
|
|
|
ARTICLE VII. MISCELLANEOUS
|
|
29
|
|
7.1
|
FEES AND EXPENSES
|
|
29
|
|
7.2
|
SEVERABILITY
|
|
29
|
|
7.3
|
CONSENT TO JURISDICTION
|
|
29
|
|
7.4
|
DISPUTE RESOLUTION PROCEDURES
|
|
30
|
|
7.5
|
BROKERS
|
|
32
|
|
7.6
|
ENTIRE AGREEMENT; AMENDMENTS
|
|
32
|
i
|
7.7
|
NOTICES
|
|
33
|
|
7.8
|
NO WAIVER
|
|
34
|
|
7.9
|
HEADING
|
|
34
|
|
7.10
|
SUCCESSORS AND ASSIGNS
|
|
34
|
|
7.11
|
NO THIRD PARTY BENEFICIARIES
|
|
34
|
|
7.12
|
GOVERNING LAW
|
|
34
|
|
7.13
|
FURTHER ASSURANCES
|
|
34
|
|
7.14
|
RELATIONSHIP OF THE PARTIES
|
|
35
|
|
7.15
|
PUBLICITY
|
|
35
|
|
7.16
|
NUMBER AND GENDER OF WORDS
|
|
35
|
|
7.17
|
INTERPRETATION
|
|
36
|
|
7.18
|
COUNTERPARTS
|
|
36
|
ii
TABLE OF EXHIBITS
|
Exhibit A - Definitions
|
|
|
Exhibit B - JDA Amendment
|
|
|
Exhibit C - Schedule of Exceptions
|
|
|
Exhibit D - Director Agreement
|
|
EXHIBIT 10.12
DIGIMARC CORPORATION
STRATEGIC INVESTMENT AGREEMENT
THIS STRATEGIC INVESTMENT AGREEMENT
(this “AGREEMENT”) is made as of September 17, 2000 by
and between MACROVISION CORPORATION, a Delaware corporation (the
“INVESTOR”), and DIGIMARC CORPORATION, a Delaware
corporation (the “COMPANY”), (each a
“PARTY”, collectively, the “PARTIES”).
Capitalized terms used in this Agreement and not otherwise defined
are defined in EXHIBIT A, attached hereto and incorporated by
reference herein.
A.
The Investor and the Company believe
that a more extensive business relationship between them would be
mutually advantageous.
B.
As part of such current and
potential business relationship, the Parties desire that the
Investor further increase its equity stake in the Company by
purchasing additional shares of the Company’s Common Stock
(the “COMMON STOCK”, and such shares, the
“ADDITIONAL SHARES”) at a purchase price of the lower
of (i) $20.00 per share and (ii) the price to be paid for the
Common Stock by Koninklijke Philips Electronics N.V. or an
Affiliate thereof (“PHILIPS”) for the purchase of
approximately twelve percent (12%) of the issued and outstanding
Common Stock pursuant to the Strategic Investment Agreement between
the Company and Philips of even date herewith (the “PHILIPS
STRATEGIC INVESTMENT AGREEMENT”), such that after its
purchase of the Additional Shares the Investor will hold an
aggregate amount of Common Stock equal to the Macrovision
Percentage (defined below). The “MACROVISION
PERCENTAGE” of the Common Stock shall be an amount equal to
twelve and five tenths of a percent (12.5%) of the issued and
outstanding Common Stock at the Closing, including the 924,475
shares of Common Stock currently owned by the Investor (the
“ORIGINAL SHARES”) and the Additional Shares to be
issued to the Investor hereunder and the shares issued or to be
issued pursuant to the Philips Strategic Investment Agreement, but
excluding shares subject to warrants, options or other contracts
for the sale of the Common Stock existing on the date of this
Agreement. If the Company issues any warrants, options or other
contracts for the purchase of Common Stock after the date of this
Agreement but prior to the Closing (other than pursuant to the
Company’s existing employee stock purchase plans), then the
Investor may purchase (at its option) a number of shares of Common
Stock such that the Macrovision Percentage may be calculated
including the Common Stock available for issuance under such
warrants, options and other contracts.
NOW, THEREFORE, in consideration of
the mutual promises contained herein and made pursuant hereto, and
good and valuable consideration, receipt of which is hereby
acknowledged, the Parties hereto do hereby agree as
follows:
1
ARTICLE I.
Purchase and Sale of Additional
Shares
1.1
PURCHASE AND SALE OF THE ADDITIONAL
SHARES.
Subject to the terms and conditions
hereof, the Company will issue and sell to the Investor, and the
Investor will purchase from the Company, at the Closing (defined in
Section 1.2), that number of Additional Shares at a purchase price
per share (the “SHARE PRICE”) equal to the lower of (a)
$20.00 per share and (b) the price for the Common Stock to be paid
by Philips pursuant to the Philips Strategic Investment Agreement,
such that the Investor will hold an aggregate amount of Common
Stock equal to the Macrovision Percentage. The “TOTAL
PURCHASE PRICE” shall be the Share Price multiplied by the
number of Additional Shares purchased by the Investor, such number
of shares when taken together with the Original Shares not to
exceed the Macrovision Percentage.
1.2
THE CLOSING.
The purchase and sale of the
Additional Shares shall take place at the offices of Morrison &
Foerster LLP, 425 Market Street, San Francisco, California, on
October 19, 2000, or at such other time and place as the Company
and the Investor mutually agree upon orally or in writing (the
“CLOSING”). At the Closing, the Company shall deliver
to the Investor a stock certificate representing the Additional
Shares purchased by the Investor, and the Investor shall pay the
Total Purchase Price by wire transfer of immediately available
funds in the manner requested by the Company, all in accordance
with Section 1.1.
1.3
JDA AMENDMENT.
On the date hereof the Parties will
execute an amendment to the Joint Development Agreement between
them, dated as of August 22, 1997 and as previously amended, which
is attached hereto as EXHIBIT B (the “JDA AMENDMENT”).
[***] The remaining terms and conditions are more fully set forth
in the JDA Amendment.
ARTICLE II.
Representations and
Warranties
2.1
REPRESENTATIONS AND WARRANTIES OF
THE COMPANY.
Except as set forth on the Schedule
of Exceptions, attached hereto as EXHIBIT C (“SCHEDULE OF
EXCEPTIONS”), or as disclosed in the SEC Documents (as
defined in Section 2.1(f)), the Company represents and warrants to
the Investor as follows:
2
(a)
ORGANIZATION AND
QUALIFICATION.
The Company is a corporation duly
organized and existing in good standing under the laws of the
jurisdiction in which it is incorporated, and has the requisite
corporate power to own its properties and to carry on its business
as now being conducted. The Company is duly qualified as a foreign
corporation to do business and is in good standing in every
jurisdiction in which the nature of the business conducted or
property owned by it makes such qualification necessary and where
the failure to qualify would have a Material Adverse Effect with
respect to the Company.
(b)
AUTHORIZATION;
ENFORCEMENT.
The Company has the requisite
corporate power and authority to enter into and perform this
Agreement and to issue the Additional Shares in accordance with the
terms hereof. The execution and delivery by the Company of this
Agreement and the consummation of the transactions contemplated
hereby have been duly authorized by the Company’s Board of
Directors, and no further consent or authorization of the Company
or its Board of Directors or stockholders is required. This
Agreement has been duly executed and delivered by the Company.
Subject to the Company’s receipt of the Total Purchase Price,
this Agreement constitutes the valid and binding obligation of the
Company enforceable against the Company in accordance with its
respective terms, except as such enforceability may be limited by
applicable insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally the enforcement
of, creditors’ rights and remedies or by equitable principles
of general application.
(c)
CAPITALIZATION.
The authorized capital stock of the
Company consists of 100,000,000 shares of Common Stock, of which as
of September 13, 2000, 13,085,930 shares were issued and
outstanding and 5,000,000 shares of Preferred Stock, none of which
is outstanding. All of such outstanding shares have been validly
issued and are fully paid and nonassessable. As of September 15,
2000, the Company has: (1) granted options to purchase a total of
4,028,438 shares of Common Stock; (2) issued warrants covering
150,000 shares of Common Stock; (3) not entered into other
contracts covering the future issuance of any shares of Common
Stock; (4) reserved for issuance 1,167,470 shares of Common Stock
under its employee stock option plans; and (5) reserved for
issuance 575,603 shares of Common Stock under its employee stock
purchase plans. The Company has furnished to the Investor true and
correct copies of the Company’s Certificate of Incorporation
as in effect on the date hereof (the “CERTIFICATE OF
INCORPORATION”) and the Company’s By-laws, as in effect
on the date hereof (the “BY-LAWS”).
(d)
VALIDITY OF ADDITIONAL
SHARES.
The Additional Shares, when issued
in accordance with the terms of this Agreement, will be validly
issued, fully paid and nonassessable.
3
(e)
NO CONFLICTS.
The execution, delivery and
performance by the Company of this Agreement and the consummation
by the Company of the transactions contemplated hereby do not (i)
result in a violation of the Company’s Certificate of
Incorporation or By-laws, or (ii) conflict with, or constitute a
default (or an event which with material notice or lapse of time or
both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any
material agreement, material indenture or material instrument to
which the Company is a Party, or result in a violation of any law,
rule, regulation, order, judgment or decree applicable to the
Company or by which any property or asset of the Company is bound
or affected (except for such conflicts, defaults, terminations,
amendments, accelerations, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse
Effect on the Company). No action, suit, dispute or proceeding is
pending or, to the best knowledge of the Company, threatened
against the Company which, if adversely determined, would prevent
the Company from carrying out its obligations under this Agreement
or which would have a Material Adverse Effect on the Company or on
any of the Company’s Intellectual Property (as defined in
Section 2(m)(i) hereof). The business of the Company is not being
conducted in violation of any law, ordinance or regulation of any
Governmental Authority, except for possible violations which either
singly or in the aggregate do not and will not have a Material
Adverse Effect with respect to the Company. Except as contemplated
by this Agreement, the Company is not required to obtain any
consent, authorization or order of, or make any filing or
registration with, any court or Governmental Authority in order for
it to execute, deliver or perform any of its obligations under this
Agreement.
(f)
SEC DOCUMENTS, FINANCIAL
STATEMENTS.
Since December 7, 1999, the Company
has filed all reports, schedules, forms, statements and other
documents required to be filed by it with the SEC pursuant to the
reporting requirements of the Exchange Act (all filings with the
SEC since such date through the date of this Agreement are
hereinafter the “SEC DOCUMENTS”). As of their
respective dates, the SEC Documents complied in all material
respects with the requirements of the Exchange Act and the rules
and regulations of the SEC promulgated thereunder applicable to
such SEC Documents, and none of the SEC Documents (when read
together with all exhibits included therein and financial statement
schedules thereto and documents (other than exhibits) incorporated
by reference) contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. The
financial statements of the Company included in the SEC Documents
comply as to form in all material respects with applicable
accounting requirements and the published rules and regulations of
the SEC with respect thereto. Such financial statements have been
prepared in accordance with U.S. generally accepted accounting
principles (“GAAP”) applied on a consistent basis
during the periods involved (except (i) as may be otherwise
indicated in such financial
4
statements or the notes thereto, or (ii) in the
case of unaudited interim statements, to the extent they may not
include footnotes or year-end adjustments or may be condensed or
summary statements) and fairly present in all material respects the
consolidated financial position of the Company as of the dates
thereof and the consolidated results of its operations and cash
flows for the periods then ended (subject, in the case of unaudited
statements, to normal year-end audit adjustments).
(g)
LIABILITIES.
The Company has no debt, obligation,
duty or liability of any nature including any unknown, undisclosed,
unmatured, unaccrued, unasserted, contingent, indirect,
conditional, implied, vicarious, derivative, joint, several or
secondary liability, regardless of whether such debt, obligation,
duty or liability would be required to be disclosed on a balance
sheet prepared in accordance with GAAP, consistently applied, and
regardless of whether such debts, obligations, duties or
liabilities are immediately due and payable (hereinafter,
“LIABILITIES”), and the executive officers of the
Company have no knowledge that could result in any such debts,
obligations, duties or liabilities of the Company
except:
(i)
Those Liabilities disclosed in the
SEC Documents; or
(ii)
Those Liabilities reflected or
reserved against on the Company’s June 30, 2000 balance sheet
(the “INTERIM BALANCE SHEET”) or incurred by the
Company in the ordinary course of business since June 30, 2000,
none of which individually or in the aggregate had or will have a
Material Adverse Effect on the business of the Company or its
property, assets, financial condition, earnings, profits or
prospects or which would have a material adverse effect on any of
the Intellectual Property.
(h)
OFFERING.
Assuming (i) the accuracy of the
representations and warranties of the Investor contained in Section
2.2 hereof and (ii) that the principal office of the Investor is at
1341 Orleans Drive, Sunnyvale, California, the offer, issuance, and
sale of the Additional Shares are and will be exempt from the
registration and prospectus delivery requirements of the Securities
Act and are exempt from the registration, permit, or qualification
requirements of all applicable state securities laws.
(i)
SUBSIDIARIES.
The Company does not presently own
or control, directly, or indirectly, any interest in any other
corporation, association, partnership, or other business
entity.
(j)
LITIGATION.
There are no civil, criminal or
administrative actions, suits, claims, hearings or proceedings
pending, initiated or, to the best knowledge of the executive
officers of the
5
Company, threatened, against the Company which,
if decided adversely, are reasonably expected to have a Material
Adverse Effect with respect to the Company. There are no actions,
suits, claims, hearings or proceedings pending, initiated or, to
the best knowledge of the Company, threatened, by the Company
against any other Person for claims in excess of
$500,000.
(k)
WATERMARKING TECHNOLOGY.
There is no present intention by the Company to
depart from its business plan of aggressively developing and
marketing its watermarking technology.
(l)
ABSENCE OF CERTAIN
CHANGES.
Since the date of the
Company’s most recent quarterly report filed with the SEC
(the “AUDIT DATE”), the Company has conducted its
businesses only in, and has not engaged in any material transaction
other than according to, the ordinary and usual course of its
business. Without limiting the generality of the foregoing, since
the Audit Date there has not been any damage, destruction or other
casualty or loss with respect to any asset or property owned,
leased or otherwise used by the Company or any of its subsidiaries,
whether or not covered by insurance, which will have a Material
Adverse Effect on the Company.
(m)
INTELLECTUAL PROPERTY.
(i)
The Company is the sole legal and
beneficial owner of all intellectual property, proprietary
technology and proprietary information held or used in the business
of the Company (the “INTELLECTUAL PROPERTY”), except
for Intellectual Property that is the subject of any license for
Third Party Intellectual Property Rights (a “THIRD PARTY
INTELLECTUAL PROPERTY LICENSE”) or commercially available or
user licenses. Notwithstanding the foregoing, the Company makes no
warranty about third party patents that have not, to the knowledge
of the Company’s executive officers, been asserted in writing
against the Company as of the date hereof, other than: (A) third
party patents that the Company has asked outside legal counsel to
analyze to determine whether such patents apply to the
Company’s products; (B) any third-party patent for which the
Company’s in-house attorneys have prepared a written analysis
relating to the relevance of such patent to the Company’s
products; (C) third-party patents that have been identified by or
brought to the attention to any of the executive officers of the
Company (which includes its Chief Technology Officer and the
general managers of each of its three lines of business) or the
Vice President of Engineering or the Vice President of Corporate
Development of the Company as being potentially infringed by the
Company’s products or methods, or (D) third party patents
that the Company is willfully infringing.
(ii)
With the exception of immaterial
licenses and agreements entered into in the normal course of
business and except for as set forth in the Schedule of Exceptions,
[***].
6
(iii)
The Company is in compliance in all
material respects with all Third Party Intellectual Property
Licenses.
(iv)
The Company is not, nor will it be
as a result of the execution and delivery of this Agreement or the
performance of obligations hereunder in violation or breach of any
contracts as to which the Company licenses or sublicenses the
Intellectual Property or any Third Party Intellectual Property
Licenses.
(v)
The Company has the right to license
to third parties the use of the Intellectual Property other than
commercially available and user software licenses and other than
the Intellectual Property that, in the aggregate, would be
immaterial to the Company’s business.
(vi)
All registrations and filings
relating to the Company’s Intellectual Property are in good
standing. All maintenance and renewal fees necessary to preserve
the rights of the Company in respect of its Intellectual Property
have been made. The registrations and filings relating to the
Company’s Intellectual Property are proceeding, and there are
no facts of which the executive officers of the Company have
knowledge which could significantly undermine those registrations
or filings or reduce to a significant extent the scope of
protection of any patents arising from such applications beyond
that which ordinarily might occur in a patent prosecution
proceeding. Notwithstanding the foregoing, the Company only makes
the foregoing warranties under this subsection (vi) to the
knowledge of the Company’s executive officers as of the
Closing as applied to the Third Party Intellectual Property
Rights.
(vii)
The manufacturing, marketing,
distribution or sale of any product currently manufactured,
marketed, distributed or sold by, or identified for development by,
the Company, any of its subsidiaries, licensees or sublicensees in
the countries where the Company has conducted or proposes to
conduct such activities does not and would not infringe, induce
infringement or contributorily infringe the intellectual property
rights throughout the world of any third party (collectively,
“THIRD PARTY INTELLECTUAL PROPERTY RIGHTS”), except the
Company makes no warranty about third party patents that have not,
to the knowledge of the Company’s executive officers, been
asserted in writing against the Company as of the date hereof,
other than: (A) third party patents that the Company has asked
outside legal counsel to analyze to determine whether such patents
apply to the Company’s products; (B) any third-party patent
for which the Company’s in-house attorneys have prepared a
written analysis relating to the relevance of such patent to the
Company’s products; (C) third-party patents that have been
identified by or brought to the attention to any of the executive
officers of the Company or the Vice President of Engineering or the
Vice President of Corporate Development of the Company as being
potentially infringed by the Company’s products or methods,
or (D) third party patents that the Company is willfully
infringing.
(viii)
Except as set forth in the Schedule
of Exceptions, there are no allegations, claims or proceedings
instituted or pending which challenge the rights
7
possessed by the Company to use the Intellectual
Property or the validity or effectiveness of the Intellectual
Property, including without limitation any interferences,
oppositions, cancellations or other contested
proceedings.
(ix)
There are no outstanding claims or
proceedings instituted or pending by any third party challenging
the ownership, priority, scope or validity or effectiveness of any
Intellectual Property.
(x)
There are no Third Party
Intellectual Property Rights that would be infringed by the
continued practice of any technologies previously used or presently
used by the Company, except the Company makes no warranty about
third party patents that have not, to the knowledge of the
Company’s executive officers, been asserted in writing
against the Company as of the date hereof, other than: (A) third
party patents that the Company has asked outside legal counsel to
analyze to determine whether such patents apply to the
Company’s products; (B) any third-party patent for which the
Company’s in-house attorneys have prepared a written analysis
relating to the relevance of such patent to the Company’s
products; (C) third-party patents that have been identified by or
brought to the attention to any of the executive officers of the
Company or the Vice President of Engineering or the Vice President
of Corporate Development of the Company as being potentially
infringed by the Company’s products or methods, or (D) third
party patents that the Company is willfully infringing.
(xi)
Except as set forth in the Schedule
of Exceptions, to the knowledge of the executive officers of the
Company, there is no unauthorized use, infringement or
misappropriation of the Intellectual Property by any third party,
including any employee or former employee of the Company or any of
its subsidiaries, except for use, infringement or misappropriation
that would not have a Material Adverse Effect.
(xii)
The Company has taken commercially
reasonable measures to maintain the confidentiality of the
inventions, trade secrets, formulae, know-how, technical
information, research data, research raw data, laboratory
notebooks, procedures, designs, proprietary technology and
information of the Company, and all other information the value of
which to the Company is contingent upon maintenance of the
confidentiality thereof.
(n)
PAYMENTS.
To the knowledge of the executive
officers of the Company, none of the current stockholders,
directors, officers, representatives, agents or employees of the
Company (i) has used or is using any corporate funds for any
illegal or improper contributions, gifts, entertainment or other
unlawful expenses, (ii) has used or is using any corporate funds
for any direct or indirect unlawful or improper payments to any
domestic government officials or employees, (iii) has established
or maintained, or is maintaining, any unlawful, improper or
unrecorded fund of corporate monies or other properties, (iv) has
made any false or fictitious entries on the books and records of
the Company, (v) has made any bribe, rebate, payoff, influence
payment, kickback or other unlawful or
8
improper payment of any nature using corporate
funds or otherwise on behalf of the Company, or (vi) has made any
material favor or gift that is not deductible for federal income
tax purposes using corporate funds or otherwise on behalf of the
Company.
(o)
REGISTRATION RIGHTS.
The Company has not granted
registration rights with respect to the Company’s securities,
except as set forth in the Company’s Second Amended and
Restated Investor Rights Agreement, dated as of November 2,
1999.
(p)
FULL DISCLOSURE.
No representation or warranty made
by the Company in this Agreement nor any of the exceptions,
qualifications or other information set forth in the Schedule of
Exceptions (i) contains any statement that is false or misleading
with respect to any material fact, or (ii) omits to state any
material fact that is necessary to make the statements made in the
context in which made, not false or misleading. Notwithstanding
anything in the foregoing to the contrary, nothing in this
Agreement shall require the Company to provide to the Investor
information which (A) the Company must, under confidentiality
obligations to third parties, not disclose to the Investor; (B) is
protected by the attorney-client privilege of the Company; or (C)
is the Company’s attorney work product.
(q)
DISCLAIMER.
The Company shall not be deemed to
have made to the Investor any representation or warranty other than
as expressly made by the Company in this Section 2.1. Without
limiting the generality of the foregoing, and without prejudice to
any express representations and warranties made by the Company in
this Section 2.1, the Company makes no representation or warranty
to the Investor with regard to any projections, estimates or
budgets or as to any matters addressed in other materials
previously delivered to or made available to the Investor with
respect to future revenues, expenses, expenditures or future
results of operations. Within the limits of the foregoing
disclaimer, nothing in this Section 2.1(q) shall limit any remedy
that may be available to the Investor pursuant to Applicable
Law.
2.2
REPRESENTATIONS AND WARRANTIES OF
THE INVESTOR.
The Investor hereby makes the
following representations and warranties to the Company:
(a)
AUTHORIZATION;
ENFORCEMENT.
The Investor is a corporation duly
organized and existing in good standing under the laws of the
jurisdiction in which it is incorporated, and has the requisite
corporate power and authority to enter into and perform this
Agreement. The execution and
9
delivery of this Agreement by the Investor and
the consummation by the Investor of the transactions contemplated
hereby have been duly authorized by all necessary corporate action,
and no further consent or authorization of the Investor or its
Board of Directors or stockholders is required. This Agreement has
been duly authorized, executed and delivered by the Investor. Upon
receipt of the Additional Shares, this Agreement constitutes a
valid and binding obligation of the Investor enforceable against
the Investor in accordance with its terms, except as enforceability
may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating
to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general
application.
(b)
PRESENT OWNERSHIP.
Other than the Original Shares and
the Additional Shares to be acquired pursuant to this Agreement,
the Investor does not Beneficially Own any other securities issued
by the Company.
(c)
INVESTMENT INTENT.
The Investor is acquiring the
Additional Shares solely for the purpose of investment within the
meaning of 16 C.F.R. Section 802.9. Based upon the Company’s
representation in Section 2.1(c) regarding its issued and
outstanding stock, as a result of this investment, the Investor and
all other entities controlled by the Investor will not own more
than 12.5% of the outstanding voting securities of the Company. As
used in the preceding sentence, the term “controlled”
shall have the meaning set forth in 16 C.F.R. Section 801.1(b).
This representation and warranty is made solely for the purpose of
determining the applicability to the transactions contemplated by
this Agreement of the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, as amended (the “HSR ACT”).
(d)
NO CONFLICTS.
The execution, delivery and
performance of this Agreement by the Investor and the consummation
by the Investor of the transactions contemplated hereby do not (i)
result in a violation of the Investor’s certificate of
incorporation or by-laws or (ii) conflict with, or constitute a
default (or an event which with material notice or lapse of time or
both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any
material agreement, material indenture or material instrument to
which the Investor or any of its subsidiaries is a Party, or result
in a violation of any law, rule, regulation, order, judgment or
decree applicable to the Investor, any of its subsidiaries or by
which any property or asset of the Investor or any of its
subsidiaries is bound or affected (except in the case of subclause
(ii) for such conflicts, defaults, terminations, amendments,
accelerations, cancellations and violations as would not,
individually or in the aggregate, have a Material Adverse Effect
with respect to the Investor or materially impair the
Investor’s ability to perform its obligations under this
Agreement). No action, suit, dispute or proceeding is pending or,
to the best knowledge of the Investor, threatened against the
Investor which, if adversely
10
determined, would prevent the Investor from
carrying out its obligations under this Agreement. Except as
contemplated by this Agreement, the Investor is not required to
obtain any consent, authorization or order of, or make any filing
or registration with, any court or governmental agency in order for
it to execute, deliver or perform any of its obligations under this
Agreement or to purchase the Additional Shares in accordance with
the terms hereof.
(e)
INVESTMENT
REPRESENTATION.
The Investor understands and
acknowledges that none of the Additional Shares have been
registered or qualified under the federal or applicable state
securities laws and the Additional Shares are being sold to and
purchased by the Investor in reliance upon applicable exemptions
from such registration and qualification requirements. The Investor
is an “ACCREDITED INVESTOR” within the meaning of the
federal securities laws and acknowledges that it has been furnished
with access to, and has been afforded access to, and afforded the
opportunity to ask questions and receive answers concerning such
information pertaining to the Additional Shares, the Company, and
its assets and liabilities as it deemed necessary to decide whether
to purchase the Additional Shares pursuant to the terms of this
Agreement. The Additional Shares will be acquired by the Investor
for investment only and not with a view to any public distribution
thereof. The Investor understands that the Additional Shares are
“RESTRICTED SECURITIES” within the meaning of the
federal securities laws. The Investor agrees that it will not offer
to sell or otherwise dispose of any of the Additional Shares in
violation of the registration and qualification requirements of the
federal and applicable state securities laws. All certificates to
be delivered at the Closing evidencing the Additional Shares will
contain appropriate legends incorporating any applicable securities
laws restrictions.
(f)
DISCLAIMER.
The Investor shall not be deemed to
have made to the Company any representation or warranty other than
as expressly made by the Investor in this Section 2.2. Without
limiting the generality of the foregoing, and without prejudice to
any express representations and warranties made by the Investor in
this Section 2.2, the Investor makes no representation or warranty
to the Company with regard to any issues related to projections,
estimates or budgets or other matters previously delivered to or
made available to the Company with respect to future revenues,
expenses, expenditures or future results of operations. Nothing in
this Section 2.2(f) shall limit any remedy that may be available to
Company pursuant to Applicable Law.
11
ARTICLE III.
Covenants
3.1
[RESERVED].
3.2
INVESTOR’S STANDSTILL
AGREEMENT.
(a)
STANDSTILL PERIOD.
Subject to subsection (b) below,
during the period commencing on the Closing and ending [***] (the
“STANDSTILL Period”), the Investor agrees that, except
as specifically permitted by this Agreement, the Investor and each
of its Affiliates will not, in any manner, directly or
indirectly:
(i)
acquire, or offer or agree to
acquire, any Common Stock of the Company or any of its successors,
except by way of stock dividends or other distributions or
offerings made available to holders of Common Stock generally,
[***];
(ii)
disclose any intention, plan or
arrangement inconsistent with the foregoing; or
(iii)
enter into any discussions,
negotiations, arrangements or understanding with any third party
with respect to, or aid, abet or encourage any action prohibited
by, any of the foregoing.
(b)
EXCEPTIONS.
(i)
Notwithstanding any provision of
this Section 3.2 to the contrary, the provisions of subsection (a)
above shall terminate on the following events:
(A)
[***]; or
(B)
[***].
(ii)
Notwithstanding any provision of
this Section 3.2 to the contrary, the provisions of subsection (a)
above shall not be construed to prohibit or otherwise restrict
[***].
(c)
NOTICE OF ACQUISITION;
COMPLIANCE.
So long as the Investor complies
with this Agreement, during the Standstill Period, the Investor
agrees that within thirty (30) days following the Investor’s
acquisition of Company Securities in any open market purchase or
other purchase which is specifically permitted by this Agreement,
it will give the Company notice of such acquisition. All open
market purchases of shares of Company Securities by the Investor
and its Affiliates shall be made in compliance with this Agreement
and Applicable Laws.
12
3.3
TRANSFER.
(a)
TRANSFER RESTRICTIONS.
The Investor shall not, at any time,
directly or indirectly, sell or transfer, or offer to sell or
transfer, all or any portion of the Additional Shares acquired
pursuant to this Agreement, except:
(i)
as provided in Section
3.3(b);
(ii)
in transactions in compliance with
Rule 144 promulgated under the Securities Act, as such rule exists
on the date hereof as hereafter amended (or any successor or
similar provision governing the resale of the restricted
securities); or
(iii)
in any other bona fide sales or
transfers to any Person pursuant to an exemption from the
registration requirements of the Securities Act, but only
if:
(A)
such Person, together with all of
such Person’s Affiliates, certify to the Company that such
Person, together with such Person’s Affiliates and associates
(as defined in the Exchange Act), would not Beneficially Own or be
a member of any Group that Beneficially Owns, after such sale or
transfer, Voting Securities representing Beneficial Ownership of in
excess of 12.5% of all then outstanding Voting
Securities;
(B)
the Investor has previously
delivered to the Company an opinion of counsel reasonably
satisfactory to the Company to the effect that any sale or transfer
pursuant to this Section 3.3 is exempt from registration under the
Securities Act;
(C)
the Investor shall have notified the
Company of the proposed disposition and shall have furnished the
Company with a detailed statement of the circumstances surrounding
the proposed disposition; and
(D)
the transferee(s) agrees by written
instrument to be subject to the terms of this Agreement to the same
extent as if such transferee(s) was the original investor
hereunder.
(b)
PERMITTED TRANSFERS.
The Investor shall be permitted to
sell Company Securities that are registered pursuant to an
effective registration statement under the Securities Act under
Article IV below.
(c)
RECOVERY OF LEGAL FEES.
The Company shall be entitled to
recover from the Investor all costs and expenses (including,
without limitation, court costs and reasonable attorneys fees)
incurred by the Company in connection with the enforcement of this
Article III against the Investor, or its
13
Affiliates, and all actions or proceedings, in
any way, manner or respect arising out of or relating to the
enforcement by the Company of its rights under this Article
III.
3.4
COMPLIANCE WITH SECTION
13.
The Investor shall, promptly and at
all times after the date hereof, use Best Efforts to comply with
its obligations to make any filings required by Section 13 of the
Exchange Act..
3.5
DIRECTOR APPOINTMENTS AND
ELECTION.
At the Closing, the Company shall
appoint either John Ryan or William Krepick, whichever the Investor
shall specify, to a seat on the Company’s Board of Directors
with a term expiring at the Company’s annual shareholders
meeting
in calendar year 2003.
ARTICLE IV.
Registration
Rights
4.1
LEGEND.
(a)
LEGEND.
All certificates evidencing the
Additional Shares shall bear the following legend, to the extent
applicable, which legend will remain on such certificates until
such time as the securities represented by such certificates are no
longer subject to the legended restrictions, and there is delivered
to the Company an opinion of counsel reasonably acceptable to the
Company to the effect that such legend is no longer required (at
which time new certificates shall be issued at the Company’s
expense without such legend):
THIS SECURITY IS SUBJECT TO THE
PROVISIONS OF THE STRATEGIC INVESTMENT AGREEMENT DATED AS OF
SEPTEMBER 17, 2000 BETWEEN THE ISSUER AND MACROVISION CORPORATION
AND MAY NOT BE SOLD OR TRANSFERRED EXCEPT IN ACCORDANCE THEREWITH.
A COPY OF SUCH AGREEMENT IS ON FILE AT THE OFFICE OF THE CORPORATE
SECRETARY OF THE ISSUER. THIS SECURITY WAS SOLD IN A PRIVATE
PLACEMENT, WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933
(THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED
UNDER THE ACT OR, IN THE OPINION OF COUNSEL OR BASED ON OTHER
WRITTEN EVIDENCE IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER
OF THESE
14
SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH.
(b)
REMOVAL OF SECURITIES ACT
LEGEND.
The Company shall be obligated to
reissue promptly unlegended certificates at the request of the
Investor, if the Investor shall have obtained an opinion of counsel
reasonably acceptable to the Company to the effect that the
securities proposed to be disposed of may lawfully be so disposed
of without registration, qualification or legend.
(c)
REMOVAL OF BLUE SKY
LEGEND.
Any legend endorsed on an instrument
pursuant to applicable state securities laws and the stop-transfer
instructions with respect to such securities shall be removed upon
receipt by the Company of an order of the appropriate blue sky
authority authorizing such removal.
4.2
REGISTRATION ON FORM S-3.
If after the earlier of the [***] of
the Closing and the occurrence of an event detailed in Section
3.2(b)(i)(B) the Company shall receive from the Investor a written
request or requests (such requests shall state the number of
Registrable Securities to be disposed of and the intended methods
of disposition of such shares by the Investor) that the Company
effect a registration on Form S-3 (or any successor to Form S-3) or
any similar short-form registration statement and any related
qualification or compliance with respect to all or a part of the
Registrable Securities, the Company will:
(a)
as soon as practicable, effect such
registration and all such qualifications and compliances as may be
so requested and as would permit or facilitate the sale and
distribution of all or such portion of the Investor’s
Registrable Securities as are specified in such request; provided,
however, that the Company shall not be obligated to effect any such
registration, qualification or compliance pursuant to this Section
4.2:
(i)
if the Company shall have already
effected two (2) registrations for the Investor under this Section
4.2
(ii)
if Form S-3 (or such successor or
similar form) is not available for such offering by the Investor;
or
(iii)
if the Investor, together with the
holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable
Securities and such other securities (if any) at an aggregate
offering price to the public of less than $1,000,000; or
(iv)
if the Company shall furnish to the
Investor a certificate signed by the President or Chief Executive
Officer of the Company stating that, in the good faith
15
judgment of the Board of Directors of the
Company, it would be seriously detrimental to the Company and its
shareholders for such Form S-3 Registration to be effected at such
time, in which event the Company shall have the right to defer the
filing of the Form S-3 registration statement for a single period
of not more than ninety (90) days after receipt of the request of
the Investor under this Section 4.2 and provided that such right to
delay a request shall be exercised by the Company no more than
twice in any one-year period; or
(v)
during the period starting with the
date of filing of, and ending on the date one hundred eighty (180)
days following, the effective date of any other registration
statement filed by the Company under the Securities
Act; or
(vi)
if the Compa